伴随着个性化、精细化医美需求的持续提升，供给端产品、材料更新也在井喷。从玻尿酸的经典应用， 到胶原刺激类材料（如PLLA童颜针等）、胶原蛋白等陆续获批入场，消费者选择似乎变得格外丰富。 不过，繁荣背面也有很多隐忧。社交媒体上，馒化（面部过度填充）、假面感、移位等负面案例，又让 很多人望而却步。 那么，到底应该如何客观衡量医美前后的"年轻态"改变？在临床医生眼中，用于医美修复的主要生物材 料，各自有哪些特点？导致馒化、假面感的核心原因，到底有哪些？ 针对一系列问题，36氪近日访谈了上海交通大学医学院附属第九人民医院整复外科主任医师张余光教 授，从临床专家角度，讲述面部年轻化的客观标准，"馒化"修复等的深层逻辑，以及提升医美体验的关 键要素。 以下是对话内容（经编辑）： 为"年轻化"审美，设置客观标准 2025年，国内医美市场站在一个关键点上。 大众对于抗衰、年轻化的需求与日俱增，审美潮流也从昔日的盲目跟风，转向追求自然的"妈生 美"、"东方美"。 36氪：据你观察，大众求美的潮流、需求发生了哪些显著变化？ 张余光：我认为，近20年，中国医美市场经历了从"盲目跟风"到"自我觉醒"的过程。20年前，很多人会 想要拥 ...

面部填充材料在医美领域的超范围使用现象，是长期处于灰色地带的。 从业多年，刘菲常会遇到两类求美者：一类是拿着各类新奇项目名称网络分享贴的咨询者，这些营销概 念在刘菲看来或不可取或仅是将常见技术进行重新包装；另一类则是一味追求"即做即效"的求美者，她 们中的一些或被不正规医美机构一次性、大剂量地注射填充剂，造成不可逆的后果。 刘菲是上海交通大学医学院附属第九人民医院整复外科副主任医师，他所谈及的医美市场，更确切地说 是以注射类和光电类为代表的非手术类轻医美市场。罗兰贝格发布的《2025医美行业白皮书》显示，近 五年来，中国轻医美市场占比持续增长，预计到2030年在整个医美市场中占比达到64%。 多名受访业界人士认为，随着行业高速发展，早些年"黑医美""黑产品""医美贷"等恶性医美非法行为盛 行的1.0阶段已经过去；但进入2.0阶段后，伴随医美新产品、新材料不断问世，新技术违规应用、注射 材料超范围使用以及使用未获批医疗器械等问题时有发生。 也就是说，无论是热度持续多年的肉毒毒素、玻尿酸，还是近一年来"火"了的羟基磷灰石，它们在医美 领域应用均需要严格遵循产品说明书的适用范围（适应证）。 今年2月，摩漾生物注射用 ...

| 名称 | 成立时间 | | 轮次 | 金额 | | | --- | --- | --- | --- | --- | --- | | 柏垠生物 | 2021年 | 合成生物企业 | 战略融资 | 未披露 | 包括富华资本、广药资本及 | | | | | | | 鲸犀投资 | | 恩泽康泰 | 2017年 | 外泌体科技企业 | B轮 | 近亿元 | 中博聚力领投 | | 臻奏生物 | 2023年 | 医美材料研发商 | Pre-A轮 | 未披露 | 昆山高新集团 | | Xinú | 2017年 | 墨西哥高端香水品 牌 | 股权投资 | 未披露 | 雅诗兰黛宣布通过旗下战略 早期投资部门New Incubation Ventures | | | | | | | A (NIV) | | 修实生物 | 2020年 | 深耕多肽生物合成 领域 | A轮 | 近亿元 | 创景资本领投 | | 巨微生物 | 2024年 | 合成生物技术研发 | A+轮 | | | | | | 問 | | 未披露 | 包括金科君创 | | LAN 兰 | 2019年 | 中国纯净护肤品牌 | 少数股权投资 | 未披露 | 欧莱雅中国 ...

Core Viewpoint - Social media has become the primary information source for young cosmetic surgery consumers, with a focus on a new injectable material called Calcium Hydroxylapatite (CaHA), which is gaining popularity in the aesthetic market [3][5]. Market Overview - In the global dermal filler market, hyaluronic acid holds a dominant 77% market share, while Calcium Hydroxylapatite accounts for 7% [3]. - Merz Aesthetics' Radiesse is currently the only FDA-approved Calcium Hydroxylapatite facial filler, recently launched in China [5]. Regulatory and Compliance Issues - There are concerns regarding the high prices of these new products, leading to potential exploitation by some cosmetic institutions [6]. - Only two approved products for facial injection in China are Radiesse and Aphranel, while others are approved for non-weight-bearing bone defects [6]. - The use of Calcium Hydroxylapatite in aesthetic applications must adhere to strict regulatory standards, with a clear distinction between products intended for medical and aesthetic use [9]. Consumer Awareness and Safety - Consumers are advised to be cautious and verify the legitimacy of products before use, as many products are not intended for aesthetic applications [8][10]. - Misleading advertising and unverified information on social media pose significant risks to consumers, particularly younger individuals [10]. - The importance of using qualified medical professionals for injections is emphasized, as improper techniques can lead to serious complications [10].

Core Viewpoint - Social media has become the primary information source for young cosmetic consumers, with a growing interest in calcium hydroxyapatite (CaHA) as a regenerative injectable material, often referred to as the "hardest hyaluronic acid" [1] Market Overview - Hyaluronic acid currently holds a dominant 77% market share in the global dermal filler market, while calcium hydroxyapatite accounts for 7% [1] - Merz Aesthetics' Radiesse is the only FDA-approved calcium hydroxyapatite facial filler in the global market, recently approved in China [2] - Domestic companies such as Haohai Biological Technology, Huaxi Biological, and Juzhi Biological are actively developing calcium hydroxyapatite products, intensifying market competition [2] Regulatory and Safety Concerns - Only two calcium hydroxyapatite products are approved for facial injection in China, highlighting the limited scope of approved applications [2] - The use of calcium hydroxyapatite in cosmetic procedures is subject to strict regulatory oversight, requiring clinical trials for injectable products, which can take 6 to 7 years for approval [4] - There are concerns regarding the misuse of calcium hydroxyapatite products, with reports of unqualified products being injected in medical aesthetic clinics [2][4] Consumer Awareness and Risks - The medical aesthetic market faces challenges with misleading advertising and the promotion of unapproved products, leading to potential consumer harm [6] - Experts emphasize the importance of consumers verifying the legitimacy of products and the qualifications of practitioners before undergoing treatments [5][6] - The industry is marked by a disconnect between regulatory bodies, manufacturers, and medical aesthetic institutions, complicating compliance and consumer safety [4]

Core Viewpoint - Recent consumer complaints regarding unqualified products used in medical beauty clinics have sparked discussions about the off-label use of calcium hydroxyapatite (CaHA) aesthetic products [1][2] Industry Overview - Social media has become the primary information source for young consumers in the medical beauty sector, with many influencers promoting CaHA as a regenerative injection material [1] - In the global dermal filler market, hyaluronic acid holds a dominant 77% market share, while CaHA accounts for 7% [1] Product Approval and Market Competition - Merz Aesthetics' Radiesse is currently the only FDA-approved CaHA facial filler, which received approval from China's drug regulatory authority in March and has recently launched in the domestic market [2] - Domestic companies such as Haohai Biological Technology, Huaxi Biological, and Juzhi Biological are actively developing CaHA products, intensifying market competition [2] Regulatory and Safety Concerns - Only two approved CaHA fillers in China are indicated for facial injection, while others are approved for non-load-bearing bone defects [2] - The safety of CaHA as a biomaterial has been established since the 1970s, but its off-label use can lead to complications such as inflammation and nodules [3] Consumer Awareness and Risks - Approximately 200 CaHA products have been approved in China, primarily for orthopedic and dental use, not for aesthetic applications [4] - The regulatory framework requires medical devices and drugs to undergo strict classification and approval processes, but some manufacturers may use misleading marketing strategies [5] Recommendations for Consumers - Consumers are advised to seek treatment from reputable institutions and verify product authenticity before procedures [6] - Medical professionals performing CaHA injections must have the necessary qualifications and training to minimize risks [6] - Misleading advertising and unverified information on social media pose significant risks to consumers, particularly younger individuals [6]

公开信息显示，菲林普利是成都睿合医药旗下的医美品牌，产品由四川拜阿蒙生物材料公司研发生产。国家药监局官网信息明确其注册全称为"羟基磷灰石 生物陶瓷"，适应范围为"各种原因所致的骨缺损修复或填充；各种原因所致的软组织修复或增强，如眼球摘除或眼内容物剜除后的义眼台植入"。 日前，杭州电视台官微发布一篇名为《杭州思达芮医疗数万元打的美容针 竟是"骨科材料"疑似违规用药》的报道，再度将羟基磷灰石（CaHA）这一医美新 材料的使用乱象推向公众视野。 报道披露，今年8月，市民骆女士在杭州思达芮医疗美容诊所花费50830元，注射了宣称可以刺激胶原蛋白再生、让皮肤变得更有弹性的"菲林普利"，然而事 后发现该产品不具备面部医美注射的资质。 骆女士同时反映，该诊所仅告知产品功效，未详细说明注射部位及次数，且事后核对发现，诊所收取了鼻基底1针的费用，但她并未接受该部位注射。无独 有偶，另一位投诉人章女士也反映，其在该诊所注射"菲林普利"时，遭遇了与骆女士一样的"未注射却收费"问题。 目前，上城区卫生监督所已对杭州思达芮医疗美容诊所立案调查。而这背后，"菲林普利"是否构成"超适应证"使用？羟基磷灰石类材料在医美领域的类似应 用是否存 ...

Core Viewpoint - The article highlights the misuse of hydroxyapatite (CaHA) in the medical beauty industry, particularly focusing on a case where a patient received an injection of a product called "Filinpril" that was not approved for facial aesthetic use, raising concerns about regulatory compliance and patient safety [1][5][12]. Summary by Sections Incident Overview - A citizen named Ms. Luo spent 50,830 yuan at Hangzhou Sidarui Medical Aesthetic Clinic for an injection of "Filinpril," which was claimed to stimulate collagen regeneration but was later found to lack the necessary qualifications for facial aesthetic injections [1][3]. Product Information - "Filinpril" is a brand under Chengdu Ruihe Pharmaceutical, developed by Sichuan Baiamon Biological Materials Co., and is registered as "hydroxyapatite biological ceramics" with a focus on bone defect repair and soft tissue enhancement [3][4]. Regulatory Actions - The Hangzhou Health Supervision Bureau has initiated an investigation into the clinic, questioning whether the use of "Filinpril" constitutes "off-label" use and highlighting the need for stricter regulations in the medical beauty sector [5][8]. Market Context - Hydroxyapatite is recognized for its biocompatibility and is used in various medical applications, including bone and dental treatments. However, its introduction into the aesthetic market has led to concerns about its application beyond approved indications [7][11]. Compliance and Industry Challenges - The article discusses the prevalence of "off-label" use of medical products in the aesthetic industry, with many products being used in ways not specified in their registration, raising compliance risks [8][13]. Regulatory Developments - Recent approvals for compliant hydroxyapatite products, such as Aphranel and Radiesse, indicate a shift towards more regulated use in aesthetic applications, yet issues of off-label use persist [12][13]. Industry Regulation Efforts - The article notes ongoing efforts by various health authorities to enhance regulatory frameworks and combat illegal practices in the medical beauty industry, including the establishment of compliance guidelines and enforcement actions against unlicensed operations [15][16].

Core Viewpoint - New Oxygen Technology has launched the Miracle Youth Needle 3.0 at a price of 2999 yuan, marking the lowest price in the history of youth needles, aiming to make aesthetic medical treatments more affordable for consumers [1] Group 1: Product Launch and Pricing Strategy - The price of youth needles in the market typically ranges from 13,000 to 24,000 yuan, while New Oxygen's previous versions were priced at 4999 yuan and 5999 yuan, significantly lower than competitors [1] - The CEO of New Oxygen stated that high prices in the mainland market are due to high procurement costs and upstream manufacturers controlling retail prices, and the company aims to challenge the notion that the aesthetic medical industry must rely on high profits [1] Group 2: Supplier Relations and Challenges - New Oxygen faced pressure from upstream manufacturers, including legal threats, when it attempted to lower prices with its earlier versions, which led to conflicts over pricing and product authenticity [1] - The company has now partnered with Xihong Bio, which does not impose price controls, to ensure a stable supply chain and maintain quality service for consumers [2] Group 3: Business Expansion and Operational Insights - New Oxygen has opened 37 clinics since May 2023, with plans to exceed 50 by the end of 2025 and aims for a long-term goal of establishing a presence in 100 cities [2] - Currently, the clinic operations are not profitable due to the costs associated with establishing a central support system, but the individual clinics have achieved monthly profitability, indicating potential for future overall profitability [2]

Core Viewpoint - The price war in the "童颜针" (youthful injection) market is intensifying, with New Oxygen (SY.O) launching its 奇迹童颜3.0 at a record low price of 2999 yuan, significantly undercutting competitors whose prices range from 13,000 to 24,000 yuan [1] Group 1: Product Launch and Pricing Strategy - New Oxygen's 奇迹童颜3.0 utilizes a formulation called "塑缇妍," which is a combination of hyaluronic acid produced by Jiangsu Xihong Biological Pharmaceutical Co., Ltd. [2] - The product is part of a broader strategy where New Oxygen has previously launched versions 1.0 and 2.0, but faced disputes with upstream suppliers over pricing [3] - The upstream suppliers, including 普丽妍 and 圣博玛, demanded retail prices of 16,800 yuan and 18,800 yuan respectively, while New Oxygen priced its earlier versions at 4,999 yuan and 5,999 yuan [3][4] Group 2: Market Dynamics and Competitive Pressure - The increasing number of approved injection products has diminished the pricing control that upstream suppliers have over downstream distributors, exacerbated by aggressive pricing strategies from internet platforms [5] - Competitors like 美团 and 京东 are also engaging in significant price reductions, with 美团's subsidies bringing the price of certain products down from 6,000 yuan to around 900 yuan, and 京东 offering substantial discounts [5] - The trend indicates that downstream players are gaining more pricing power, putting additional pressure on upstream suppliers [6]